Comments to the article by O. Yu. Rebrova and co-authors «Screening at the first stage of periodical health checkup: a systematic review of long-term results»
https://doi.org/10.17749/2070-4909.2018.11.2.077-080
Abstract
The aim – to review and analyze the data on the long-term population-based efficiency of the screening procedures and other measures implemented according to Stage 1 periodical health checkup in the Russian Federation (by Order №36ан of 2015).
Material and methods. This systematic search was carried out independently by two authors who used four databases: Scientific electronic Library, Cochrane Library, Medline/PubMed, and USPSTF. They looked into systematic reviews quoted by these sources. The criteria of the screening efficacy were the total / specific mortality and disability. The quality of the systematic reviews was assessed by the two authors using the international AMSTAR questionnaire.
Results. According to the specific mortality rate, only the fecal occult blood test and the abdominal aorta ultrasonography are found to be efficient as screening methods for certain age and gender groups. The methodological quality of the studied reviews is high or medium to high. As follows from these high quality studies, the efficacy of mammography in female populations remains to be proven.
About the Author
V. A. Aksenov
Public Interregional Organization «Society of specialists in evidence based medicine».
Russian Federation
Russian Federation
Aksenov Valerii Alekseevich – MD, PhD, Vice-president.
46-2, Dmitrovskoe shosse, Moscow 127238.
References
1. Реброва О. Ю., Федяева В. К., Омельяновский В. В., Ильин М. А. Cкрининги I этапа диспансеризации: систематический обзор долгосрочной эффективности. Профилактическая медицина. 2017; 3: 5659 / Rebrova O. Yu., Fedyaeva V. K., Omelyanovsky V. V., Ilyin M. A. Stage 1 screenings of periodical health check: A systematic review of long-term efficiency. Profilakticheskaya medicina. 2017; 3: 56-59. DOI: 10.17116/ profmed201720355-59.
2. Moyer V. A. U. S. Preventive Services Task Force. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Jun 19; 156 (12): 880-91, W312. https://doi.org/10.7326/0003-4819-156-12-201206190-00424.
3. Marth C., Landoni F., Mahner S., et al. On behalf of the ESMO Guidelines Committee; Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. July 2017; 28 (4-1): iv72-iv83. https://doi.org/10.1093/annonc/mdx220.
4. Siu A. L. U. S. Preventive Services Task Force. Screening for high blood pressure in adults: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2015 Nov 17; 163 (10): 778-86. https://doi.org/10.7326/M15-2223.
5. Mayor S. Hypertension diagnosis should be based on ambulatory blood pressure monitoring, NICE recommends. BMJ. 2011; 343: d5421. https://doi.org/10.1136/bmj.d5421
6. Hodgkinson J., Mant J., Martin U., Guo B., Hobbs F. D. R., Deeks J. J., et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ. 2011; Jun 24; 342: d3621. https://doi.org/10.1136/bmj.d3621.
7. Catapano A. L., Graham I., De Backer G., et al.; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. eur Heart J. 2016 Oct 14; 37 (39): 2999-3058. Epub 2016 Aug 27. PubMed PMID: 27567407.
8. Piepoli M. F., Hoes A. W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). eur Heart J. 2016 Aug 1; 37 (29): 2315-81. https://doi.org/10.1093/eurheartj/ehw106.
9. Pinsky P. F., Prorok P. C., Yu K., et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123 (4): 592-599. https://doi.org/10.1002/cncr.30474.
10. Schroder F. H., Hugosson J., Roobol M. J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027-35. https://doi.org/10.1016/S01406736(14)60525-0.
11. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11 (8): 725-32. https://doi.org/10.1016/S1470-2045(10)70146-7.
12. Siu A. L. U. S. Preventive Services Task Force. Screening for Breast Cancer: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2016 Feb16; 164 (4): 279-96. https://doi.org/10.7326/M15-2886.
13. Gøtzsche P. C., Jørgensen K. J. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4; (6): CD001877. https://doi.org/10.1002/14651858.CD001877.pub5.
14. Siu A. L. U. S. Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U. S. Preventive Services Task Force Recommendation Statement. Ann intern Med. 2015 Dec 1; 163 (11): 861-8. https://doi.org/10.7326/M15-2345.
15. Moyer V. A. U. S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U. S. Preventive Services Task Force recommendation statement. Ann intern Med. 2012 Oct 2; 157 (7): 512-8. PubMed PMID: 22847227.
16. Krogsbøll L. T., Jørgensen K. J., Grønhøj L. C., Gøtzsche P. C. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ. 2012 Nov 20; 345: e7191. https://doi.org/10.1136/bmj.e7191.
Review
For citations:
Aksenov V.A. Comments to the article by O. Yu. Rebrova and co-authors «Screening at the first stage of periodical health checkup: a systematic review of long-term results». FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(2):77-80. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.2.077-080
Views:
1120
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 